Study Group: Hematologists and Oncologists in Private Practice (US)
Council Members in this Study Group: 462
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
Brian AbbottMedical Director of Hematology
Big Sky OncologyBrian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology (Benefis Health System) and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. Dr. Abbott's specialties include...
- Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research CenterSujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine...
- Robert Weber
Associate Director
Northern California Melanoma CenterRobert Weber, MD, is Associate Director at the Northern California Melanoma Center. He is a board-certified specialist in Internal Medicine and in Hematology and Oncology. He joined the consulting panel of physicians at NCMC in 2000 and is particularly...
Haitham Al-OkkAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer CenterHaitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology....
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
TREANDA for CLL could be a winner
May 19, 2008
Analysis by: Brian Abbott, Medical Director of Hematology,FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
-
National healthcare? Better find a new pool of physicians
May 19, 2008
Analysis by: Brian Abbott, Medical Director of Hematology,Look to England's example for ways to solve America's health-care problem | www.sltrib.com
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
-
Medicare: heading toward a crisis
May 19, 2008
Analysis by: Brian Abbott, Medical Director of Hematology,Loss of Doctors Leaves Patients Waiting | www.redorbit.com
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
-
February 19, 2008
Analysis by: Taral Patel, Oncologist,In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
New data with low and high dose of Avastin with Taxoter
-
improve Overall survival in prostate cancer
February 19, 2008
Analysis by: Taral Patel, Oncologist,Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). Data is very impressive. This may lead FDA approval in prostate cancer in next 3-6 months.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Partner
- President
- Physician - Director
- Director